Interleukin-1 blocking agents as promising strategy for prevention of anticancer drug-induced cardiotoxicities: possible implications in cancer patients with COVID-19.
Eur Rev Med Pharmacol Sci
; 25(21): 6797-6812, 2021 11.
Article
in English
| MEDLINE | ID: covidwho-1524867
ABSTRACT
Cytokines in cardiac tissue plays a key role in progression of cardiometabolic diseases and cardiotoxicity induced by several anticancer drugs. Interleukin-1ß is one on the most studied regulator of cancer progression, survival and resistance to anticancer treatments. Recent findings indicate that interleukin1-ß exacerbates myocardial damages in cancer patients treated with chemotherapies and immune check-point inhibitors. Interleukin1-ß blocking agent canakinumab reduces major adverse cardiovascular events and cardiovascular death in recent cardiovascular trials. We focalized on the main biological functions of interleukin1-ß in cancer and cardiovascular diseases, summarizing the main clinical evidence available to date in literature. Especially in the era of SARS-CoV-2 infection, associated to coagulopathies, myocarditis and heart failure, cancer patients have an increased risk of cardiovascular complications compared to general population, therefore, the pharmacological inhibition of interleukin1-ß should be discussed and considered.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Interleukin-1beta
/
Antibodies, Monoclonal, Humanized
/
Cardiotoxicity
/
COVID-19
/
Neoplasms
/
Antineoplastic Agents
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Eur Rev Med Pharmacol Sci
Journal subject:
Pharmacology
/
Toxicology
Year:
2021
Document Type:
Article
Affiliation country:
Eurrev_202111_27124
Similar
MEDLINE
...
LILACS
LIS